Fortress Biotech

Fortress Biotech FBIO Stock

$1.88   -5.527639%
Add to favorites
Market Cap
$62.70M
LOW - HIGH [24H]
$1.75 - $1.94
VOLUME [24H]
$310.61K
P/E Ratio
0.68
Earnings per share
$2.76
ISIN
US34960Q3074
Price   Prediction

Fortress Biotech Price Chart

Sorry, that's all we've gotfor now...

Fortress Biotech (FBIO) stock price today is 1.88 USD on Tech Market Small (-5.53% on the day). Updated .

Fortress Biotech FBIO Financial and Trading Overview

Fortress Biotech stock price 1.88 USD
Previous Close 1.99 USD
Open 1.92 USD
Bid 1.97 USD x 100
Ask 1.95 USD x 100
Day's Range 1.76 - 1.94 USD
52 Week Range 1.76 - 4.53 USD
Volume 310.61K USD
Avg. Volume 286.49K USD
Market Cap 62.7M USD
Beta (5Y Monthly) N/A
PE Ratio (TTM) 0.68115944
EPS (TTM) 2.76 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 5 USD

FBIO Valuation Measures

Enterprise Value -32772482 USD
Trailing P/E 0.68115944
Forward P/E -1.0681819
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.8958019
Price/Book (mrq) 0.38157094
Enterprise Value/Revenue -0.468
Enterprise Value/EBITDA 1.288

Trading Information

Fortress Biotech Stock Price History

Beta (5Y Monthly) N/A
52-Week Change -27.96%
S&P500 52-Week Change 13.32%
52 Week High 4.53 USD
52 Week Low 1.76 USD
50-Day Moving Average 2.14 USD
200-Day Moving Average 2.71 USD

FBIO Share Statistics

Avg. Volume (3 month) 286.49K USD
Avg. Daily Volume (10-Days) 231.94K USD
Shares Outstanding 33.35M
Float 21.3M
Short Ratio 19.16
% Held by Insiders 23.95%
% Held by Institutions 34.56%
Shares Short 4.61M
Short % of Float 17.88%
Short % of Shares Outstanding 13.83%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:15

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 143.04%
Operating Margin (ttm) -42.79%
Gross Margin 66.11%
EBITDA Margin -36.36%

Management Effectiveness

Return on Assets (ttm) -8.11%
Return on Equity (ttm) 102.48%

Income Statement

Revenue (ttm) 69.99M USD
Revenue Per Share (ttm) 2.13 USD
Quarterly Revenue Growth (yoy) 8.69%
Gross Profit (ttm) 46.28M USD
EBITDA -25451000 USD
Net Income Avi to Common (ttm) 91.84M USD
Diluted EPS (ttm) 2.76
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 152.19M USD
Total Cash Per Share (mrq) 4.51 USD
Total Debt (mrq) 38.95M USD
Total Debt/Equity (mrq) 22 USD
Current Ratio (mrq) 2.931
Book Value Per Share (mrq) 4.927

Cash Flow Statement

Operating Cash Flow (ttm) 125.83M USD
Levered Free Cash Flow (ttm) -26073876 USD

Profile of Fortress Biotech

Country United States
State FL
City Bay Harbor Islands
Address 1111 Kane Concourse
ZIP 33154
Phone 781 652 4500
Website https://www.fortressbiotech.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 78

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Q&A For Fortress Biotech Stock

What is a current FBIO stock price?

Fortress Biotech FBIO stock price today per share is 1.88 USD.

How to purchase Fortress Biotech stock?

You can buy FBIO shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Fortress Biotech?

The stock symbol or ticker of Fortress Biotech is FBIO.

Which industry does the Fortress Biotech company belong to?

The Fortress Biotech industry is Biotechnology.

How many shares does Fortress Biotech have in circulation?

The max supply of Fortress Biotech shares is 33.35M.

What is Fortress Biotech Price to Earnings Ratio (PE Ratio)?

Fortress Biotech PE Ratio is 0.68115944 now.

What was Fortress Biotech earnings per share over the trailing 12 months (TTM)?

Fortress Biotech EPS is 2.76 USD over the trailing 12 months.

Which sector does the Fortress Biotech company belong to?

The Fortress Biotech sector is Healthcare.

Fortress Biotech FBIO included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24774.04 USD —
-1.44
1.95B USD — 24719.38 USD — 24882.04 USD — — 1.95B USD —
us US Tech Health Care IXHC US 1368.29 USD —
-0.34
— — 1358.68 USD — 1373.65 USD — — — —
us US Tech Composite Total Return XCMP US 31061.46 USD —
-0.9
— — 30735.41 USD — 31415.87 USD — — — —
us US Tech Capital Market Composite RCMP US 113.05 USD —
-1.08
— — 111.72 USD — 114.38 USD — — — —
$2.23T
Total marketcap
$72.07B
Total volume
BTC 58.54%   •   ETH 10.09%
Dominance
Select currency